2015 05-20 Radboudumc REshape breakfast meeting Alain van Gool
1. Biomarkers in Personalized Health(care),
moving beyond Targeted Medicine
Professor of Personalized Healthcare
Head Radboud Center for Proteomics, Glycomics
and Metabolomics
Coordinator Radboud Technology Centers
Head Biomarkers in Personalized Healthcare
Prof Alain van Gool
20 May 2015
2. My mixed perspectives in personalized health(care)
8 years academia (NL, UK)
(molecular mechanisms of disease)
13 years pharma (EU, USA, Asia)
(biomarkers, Omics)
3,5 years med school (NL)
(personalized healthcare, Omics, biomarkers)
3,5 years applied research institute (NL, EU)
(biomarkers, personalized health, nutrition)
A person / citizen / family man
(adventures in EU, USA, Asia)
1991-1996 1996-1998 2009-2012
1999-2007 2007-2009 2009-2011
2011-now
2011-now
2
2
7. Biomarkers
{Biomarkers definition working group, 2001 }
Definition: ‘a characteristic that is objectively measured and evaluated as an
indicator of normal biological processes, pathogenic processes, or
pharmacologic responses to a therapeutic intervention’
Or ‘Whatever works in adding value’
Molecular biomarkers provide a molecular impression of a biological system
(cell, animal, human)
7
Genomic Proteomic Metabolomic Imaging
8. Exponential developments in biomarker technologies
• Next generation sequencing
• DNA, RNA
• Risk analysis and therapy selection
• Mass spectrometry
• Proteins, metabolites
• Monitoring of disease and treatment effects
• Imaging
• Non invasive images, real time
• Spatial view of intact organs and organisms
8
10. EC DG for Research and Innovation
Alain van Gool
Brussels, 11 Sept 2012
System biology in:
Diagnosis
Prognosis
Treatment
Monitoring
People are complex biological systems which
requires a systems biology approach
12. Biomarkers in Personalized Health(care)
an evolving role
• From only diagnosis
• To Translational Medicine
• To Personalized/Precision/Targeted Medicine
• To Personalized Health(care)
present
12
12
13. Personalized Health(care), more than pathways only
Source: Barabási 2007 NEJM 357; 4}
• People are different
• Different networks and influences
• Different risk factors
• Different preferences
13
13
24. Biomarker innovation gaps: some numbers
24
5 biomarkers/
working day
1 biomarker/
1-3 years
1 biomarker/
3-10 years
?
Eg Biomarkers in time: Prostate cancer
May 2011: n= 2,231 biomarkers
Nov 2012: n= 6,562 biomarkers
Oct 2013: n= 8,358 biomarkers
Nov 2014: n= 10,350 biomarkers
Discovery Clinical
validation/confirmation
Diagnostic
test
Number of
biomarkers
Gap 1
Gap 2
Gap 3
24
25. But …
Knowledge and Innovation gap:
1. What to measure?
2. How much can it change?
3. What should be the follow-up for me?
25
27. But …
Knowledge and Innovation gap:
1. What to measure?
2. How much can it change?
3. What should be the follow-up for me?
27
28. Most important for biomarkers in Personalized Healthcare:
Focus on the end user: the patient
28
28
29. Translation is key in Personalized Healthcare !
“I’m afraid you’re
suffering from an
increased IL-1β and
an aberrant miR843
expression”
Adapted from:
29
?
29
30. Translation is key in Personalized Healthcare !
Select personalized therapy
Treatment options
Successrates
Example from Prostate cancer patient guide
30
31. Translation is key in Personalized Healthcare !
Treatment options
Pro’sCon’s
Select personalized therapy
31
32. Translation is key in Personalized Health(care) !
Personal profile data
Knowledge
Understanding
Decision
Action
32
32
33. 33 Alain van Gool, Pharma-Nutrition 2015, 13 March 2015
Optimal targeted / precision / personalized health(care)
34. Acknowledgements
Ron Wevers
Jolein Gloerich
Hans Wessels
Monique Scherpenzeel
Dirk Lefeber
Leo Kluijtmans
Lucien Engelen
Paul Smits
Maroeska Rovers
Nathalie Bovy
Bas Bloem
and many others
www.radboudumc.nl/personalizedhealthcare
www.radboudumc.nl/research/technologycenters
www.radboudresearchfacilities.nl
alain.vangool@tno.nl
alain.vangool@radboudumc.nl
www.linkedIn.com
www.slideshare.net/alainvangool
Many collaborators
Jan van der Greef
Ben van Ommen
Bas Kremer
Lars Verschuren
Ivana Bobeldijk
Marjan van Erk
Carina de Jongh
Peter van Dijken
Robert Kleemann
Suzan Wopereis
and many others
34
And funders
CarTarDis
34
35. Biomarker innovation gaps: some numbers
37
Data from Thomson Reuters Integrity database, February 2015
Alzheimer’s Disease
Chronic Obstructive
Pulmonary Disease
Type II Diabetes Mellitis
37